Abstract: A swallowable, solid dose form composition for treating upper gastrointestinal tract distress containing bismuth subsalicylate, carbonate or bicarbonate salt, disintegrating agent, anionic or nonionic surfactant, and microcrystalline cellulose is described.

Abstract: The present invention discloses a new use of bismuth subgallate for use in the prevention and/or reduction of skin deterioration. Also disclosed is the synergistic efficacy of bismuth subgallate in combination with borneol in the prevention and/or reduction of skin deterioration.

Abstract: The invention provides Helicobacter polypeptides that can be used in vaccination methods for preventing or treating Helicobacter infection, and polynucleotides that encode these polypeptides.

Abstract: A method for preparation of a semitransparent colloidal solution of bismuth sodium tartrate generally comprises producing an aqueous solution of bismuth sodium tartrate; extracting a magma of bismuth sodium tartrate from the aqueous solution at a pH of approximately 2.2; and then dissolving the magma into a salting-in mixture. It is critical that the magma be extracted at a pH of at least 2.2 but not more than 2.3. As a result, the magma is extracted by washing with a wash liquor comprising an addition of distilled water; allowing the magma to settle out of the wash liquor; measuring the pH of the wash liquor after the magma has settled; and then decanting the wash liquor from the magma. This process is then repeated as necessary to arrive at a magma within the critical pH range, whereafter the magma is air dried in preparation for salting-in. After addition of preservative and strength testing, the base solution is diluted to an elixir strength.

Abstract: The invention relates to the unexpected discovery that bismuth-containing compounds are effective in the treatment of oral mucositis in a mammal. Thus, the invention relates, in one aspect to a method of treating oral mucositis comprising administering an effective amount of a pharmaceutically acceptable bismuth-containing compound, such as a bismuth salt or bismuth complex. In a preferred embodiment, the bismuth compound is an organic or inorganic salt such as, bismuth subsalicylate, bismuth subgallate, bismuth aluminate, bismuth citrate, bismuth subcitrate, bismuth carbonate, bismuth subcarbonate, tripotassium dicitrato bismuthate, bismuth nitrate, bismuth subnitrate, bismuth tartrate and mixtures thereof, preferably, bismuth subsalicylate and bismuth subgallate.

Abstract: The various embodiments of the present invention are directed to pentavalent antimonials, purified pentavalent antimonials, and pentavalent antimonials that are comprised of an antimonial portion and an organic moeity portion. Alternatively the present invention is directed to agents and methods of screening agents which mimic the activity of pentavalent antimonials, particularly sodium stibogluconate and glucatime. An appropriate organic moeity may be selected based upon a desired interaction (e.g. steric action) with active site of a cellular component (e.g. a PTPase). In a preferred embodiment of the present invention the active site includes a cysteine residue which may be impacted by the compositions of the present invention.

Abstract: In one embodiment, a therapeutic composition containing a pentavalent antimonial is provided. The pentavalent antimonial can be sodium stibogluconate, levamisole, ketoconazole, and pentamidine and biological equivalents of said compounds. Additionally, pentavalent antimonials that can be used in accordance with the present invention may be any such compounds which are anti-leishmaniasis agents. The therapeutic composition of this embodiment contains an effective amount of pentavalent antimonial that can be used in treating infectious diseases. The types of diseases that can be treated with the present invention include, but are not limited to, the following: diseases associated with PTPase activity, immune deficiency, cancer, infections (such as viral infections), hepatitis B, and hepatitis C. The types of cancers that the present embodiment can be used to treat include those such as lymphoma, multiple myeloma, leukemia, melanoma, prostate cancer, breast cancer, renal cancer, bladder cancer.

Abstract: A method of arresting the flow of blood and other protein containing body fluids flowing from an open wound and for promoting wound healing. In the method, a substantially anhydrous compound of a salt ferrate is provided for a unique use which, when hydrated after mixing with a victim's own blood or other aqueous media, produces Fe+++ thereby promoting clotting when applied in a paste form to the wound for a time sufficient to arrest substantial further blood and other body fluid flow from the wound. The compound is formed of a ferrate (VI) salt taken from the group consisting of H, Li, Na, K, Rb, Cs and Fr. However, to decrease or eliminate stinging sensation, the compound may be formed having a ferrate (VI) salt taken from the group consisting of Be, Mg, Ca, Sr, Ba, Ra, Ti, V, Cr, Mn, Fe, Co, Ni, Cu, Zn, Ga, Ge, Zr, Nb, Mo, Tc, Ru, Rh, Pd, Ag, Cd, In, Sn, Hf, Ta, W, Re, Os, Ir, Pt, Au, Hg, TI, Pb, Bi, Al, As, NH4 and N(C4H9)4.

Abstract: An antiinfective-free formulation for prophylactic traetment of mastitis in dry cows comprises a seal formulation having approximately 65% by weight of bismuth sub-nitrate in a gel based on aluminum stearate. The seal formulation is prepared by adding the bismuth sub-nitrate to the gel base in at least two separate stages.

Abstract: The invention provides methods for the treatment and/or prevention of recurrence of a gastrointestinal disorder associated with Helicobacter pylori in a patient requiring said treatment and/or prevention, which comprise administering to the patient a therapeutically effective amount of a first antibiotic which is an ansamycin and a therapeutically effective amount of at least a second antibiotic or antimicrobial agent. The invention also provides pharmaceutical compositions for use in the methods of the invention.

Abstract: The invention relates to the unexpected discovery that bismuth-containing compounds are effective in the treatment of oral mucositis in a mammal. Thus, the invention relates, in one aspect to a method of treating oral mucositis comprising administering an effective amount of a pharmaceutically acceptable bismuth-containing compound, such as a bismuth salt or bismuth complex. In a preferred embodiment, the bismuth compound is an organic or inorganic salt such as, bismuth subsalicylate, bismuth subgallate, bismuth aluminate, bismuth citrate, bismuth subcitrate, bismuth carbonate, bismuth subcarbonate, tripotassium dicitrato bismuthate, bismuth nitrate, bismuth subnitrate, bismuth tartrate and mixtures thereof, preferably, bismuth subsalicylate and bismuth subgallate.

Abstract: The invention relates to concomitant treatment with bismuth compounds, other antibacterial compounds, and/or antibiotics in oral-topical and peroral dosage forms to eradicate H. pylori from its niches both in the dental plaque and in the gastric mucosa in order to improve the ulcer cure rate and prevent ulcer relapse. The invention also provides oral topical dosage forms with pharmaceutically usable bismuth compounds, other antibacterial compounds, and/or antibiotics that eradicate or reduce H. pylori in dental plaque. The invention further provides for treatment with bismuth compounds, other antibacterial compounds, and/or antibiotics which are effective against Campylobacter rectus and Treponema denticola which are responsible for causing halitosis. The invention also provides bismuth compounds which have applications in wound healing, particularly in ocular and dermal wound healing.

Abstract: A method is described to treat or prevent sepsis and septic shock in a subject by administering a Group V metal chelated by a complexing agent such as thiol compounds in the form of a metal:complexing agent, wherein the metal is selected from the group consisting of bismuth, antimony and arsenic. Methods for modulating the immune system are also disclosed.

Abstract: This invention provides for a method for treatment of corneal and dermal wounds by administering bismuth compounds in topical dosage forms. Bismuth compounds cause stimulation of release of growth factors in damaged tissue to promote regeneration of epithelial cells and hence accelerate wound healing. These bismuth compounds also have good antimicrobial activity against several anaerobic bacteria involved in diaper rash exacerbation.

Abstract: Compounds with fungicidal and insecticidal properties having formula wherein X is N or CH; Z is O, S or NR8; A is hydrogen, halo, cyano, (C1-C12)alkyl, or (C1-C12)alkoxy; R1 and R8 are independently hydrogen or (C1-C4)alkyl; R2 is hydrogen, (C1-C12)alkyl, halo(C1-C12)alkyl, (C3-C7)cycloalkyl, halo(C3-C7)cycloalkyl, (C2-C8)alkenyl, halo(C2-C8)alkenyl, (C2-C8)alkynyl, halo(C2-C8)alkynyl, aryl, aralkyl, heterocyclic, heterocyclic(C1-C4)alkyl or C(R10)═N—OR9; R3 is hydrogen, (C1-C12)alkyl, halo(C1-C12)alkyl, (C3-C7)cycloalkyl, halo(C3-C7)cycloalkyl, (C2-C8)alkenyl, halo(C2-C8)alkenyl, (C2-C8)alkynyl, halo(C2-C8)alkynyl, aryl, aralkyl, aryl(C3-C7)cycloalkyl, heterocyclic or heterocyclic(C1-C4)alkyl; R4 and R5 are independently hydrogen, (C1-C12)alkyl, halo(C1-C12)alkyl, (C3-C7)cycloalkyl, halo(C3-C7)cycloalkyl, (C2-C8)alkenyl, halo(C2-C8)alkenyl, (C2-C8)alkynyl, halo(C2-C8)alkynyl, halo, cyano, (C1-C4)alkoxycarbonyl, aryl, aralkyl, aryl(C3-C7)cycloalkyl, heterocyclic or heterocyclic(C1

Abstract: An antiinfective-free formulation for prophylactic treatment of mastitis in dry cows comprises a seal formulation having approximately 65% by weight of bismuth sub-nitrate in a gel based on aluminum stearate. The seal formulation is prepared by adding the bismuth sub-nitrate to the gel base in at least two separate stages.

Abstract: The present invention relates to mucoadhesive compositions comprising a safe and effective amount of a gastrointestinal active; from about 1.5% to about 10%, by weight of the composition, of a clay component; and from about 0.01% to about 1%, by weight of the composition, of a gum component. Alternatively, the clay component can be a titanium dioxide or a silicone dioxide component. The mucoadhesive compositions also preferably comprise up to about 2% by weight of the composition, of a non-ionic component such as methyl cellulose. The present invention also relates to methods of prevention and treatment of gastrointestinal tract disorders in humans or lower animals by orally administering a composition of the present invention.

Abstract: An antiinfective-free formulation for prophylactic treatment of mastitis in dry cows comprises a seal formulation having approximately 65% by weight of bismuth sub-nitrate in a gel based on aluminium stearate. The seal formulation is prepared by adding the bismuth sub-nitrate to the gel base in at least two separate stages.

Abstract: The present invention provides a topical pharmaceutical composition for wound healing, which comprises (a) borneol and (b) bismuth subgallate in effective amounts. The topical pharmaceutical composition is capable of enhancing wound healing with minor irritations to injured skin, and preventing formation of scars or granulation tissues so as to help regenerate the skin with normal tenderness and appearances.

Abstract: Compounds with fungicidal and insecticidal properties having formula ##STR1## wherein X is N or CH; Z is O, S or NR.sub.8 ; A is hydrogen, halo, cyano, (C.sub.1 -C.sub.12)alkyl, or (C.sub.1 -C.sub.12)alkoxy; R.sub.1 and R.sub.8 are independently hydrogen or (C.sub.1 -C.sub.4)alkyl; R.sub.2 is hydrogen, (C.sub.1 -C.sub.12)alkyl, halo(C.sub.1 -C.sub.12)alkyl, (C.sub.3 -C.sub.7)cycloalkyl, halo(C.sub.3 -C.sub.7)cycloalkyl, (C.sub.2 -C.sub.8)alkenyl, halo(C.sub.2 -C.sub.8)alkenyl, (C.sub.2 -C.sub.8)alkynyl, halo(C.sub.2 -C.sub.8)alkynyl, aryl, aralkyl, heterocyclic, heterocyclic(C.sub.1 -C.sub.4)alkyl or C(R.sub.10).dbd.N--OR.sub.9 ; R.sub.3 is hydrogen, (C.sub.1 -C.sub.12)alkyl, halo(C.sub.1 -C.sub.12)alkyl, (C.sub.3 -C.sub.7)cycloalkyl, halo(C.sub.3 -C.sub.7)cycloalkyl, (C.sub.2 -C.sub.8)alkenyl, halo(C.sub.2 -C.sub.8)alkenyl, (C.sub.2 -C.sub.8)alkynyl, halo(C.sub.2 -C.sub.8)alkynyl, aryl, aralkyl, aryl(C.sub.3 -C.sub.7)cycloalkyl, heterocyclic or heterocyclic(C.sub.1 -C.sub.4)alkyl; R.sub.4 and R.sub.

Abstract: The subject invention encompasses methods for prevention and treatment of a human or lower animal subject having a gastrointestinal disorder caused or mediated by one or more intestinal helminths comprising administering to the subject bismuth and one or more antimicrobials. The subject invention also encompasses compositions comprising bismuth and one or more antimicrobials for the prevention and treatment of a human or lower animal subject having a gastrointestinal disorder caused or mediated by one or more intestinal helminths.

Abstract: An essentially water-insoluble compound of bismuth and polyacrylic acid disperses well in the bowel and forms a good mucoadhesive covering of the bowel wall. Thus in patients with inflammatory bowel disease the bismuth is held in intimate contact to the inflamed tissue of the bowel. Two processes are provided for preparing said water-insoluble compounds.

Abstract: Therapeutic compositions for the treatment of infectious diseases are disclosed. These compositions comprise xanthones and xanthone derivatives, such as 2,3,4,5,6-pentahydroxyxanthone. Also disclosed are methods for the treatment of infectious diseases using such compounds.

Abstract: The subject invention encompasses methods for the prevention and treatment of a human or lower animal subject having a gastrointestinal disorder caused or mediated by one or more intestinal helminths comprising administering bismuth to the subject.

Abstract: This invention relates to preservative compositions which comprise a biocidal metal compound and an fungicidal compound containing a triazole group. Methods of treating wood with the composition are also described.

Abstract: Diethylenetriaminepentaacetic acid monoamide derivatives, their complexes and complex salts, containing an element of atomic numbers 21-29, 31, 32, 39, 42-44, 49 or 57-83, pharmaceutical agents containing these compounds, their use as contrast media and process for their production.

Abstract: The use is described of both (i) ranitidine bismuth citrate and (ii) one or more Helicobacter pylori-inhibiting antibiotics in treating or preventing gastrointestinal disorders.Pharmaceutical compositions containing both (i) and (ii) and methods for the preparation of pharmaceutical compositions containing (i) and (ii) are also described.

Abstract: The use is described of both (i) ranitidine bismuth citrate and (ii) one or more Helicobacter pylori-inhibiting antibiotics in treating or preventing gastrointestinal disorders.Pharmaceutical compositions containing both (i) and (ii) and methods for the preparation of pharmaceutical compositions containing (i) and (ii) are also described.

Abstract: The present invention is directed to a method for the treatment of Helicobacter pylori infection wherein a composition containing protease and an antibacterial agent as active ingredients, which can remove Helicobacter pylori from a stomach at high probability without causing side effects or the occurrence of resistant bacteria, and which can treat and prevent peptic ulcer caused by Helicobacter pylori infection and can prevent the recurrence of peptic ulcer is employed.

Abstract: The present invention provides new and structurally diverse compositions comprising compounds of the general formula: ##STR1## Wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, and R.sup.5 are the same or different and are --CO--(CH.sub.2).sub.y --SH, --(CH.sub.2).sub.2 --SH, --SO.sub.2 --(SH.sub.2).sub.t --SH,--SH,--(CH.sub.2).sub.q --COOH, and --(CH.sub.2).sub.v --CONR.sup.6 R.sup.7, provided at least one of R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 is a sulfur containing moiety; n is 0 to about 10; i is 2 to about 5; j is 2 to about 5; y is 1 to about 5; z is 1 to about 6; t is 1 to about 5; q is 1 to about 5; v is 1 to about 5; R.sup.6 is H, alkyl, hydroxyalkyl, polyhydroxyalkyl, arylalkyl or alkoxyalkyl; R.sup.7 is H, alkyl, hydroxyalkyl, polyhydroxyalkyl, arylalkyl or alkoxyalkyl; and R.sup.7 can be polyamine when R.sup.6 is H.Methods for imaging using compositions of the invention are also provided.

Abstract: Method for the treatment of human and lower animals having an infectious gastrointestinal disorder, comprising the step of administering from about 50 to about 5000 milligrams of bismuth to said subject, per day, for from 3 to 56 days. Preferred processes also include a step for performing a diagnostic step on the subject for detection of campylobacter-like organism infection of the subject.

Abstract: A compound of formula (I): ##STR1## wherein: R.sub.1 is a hydroxy group or an amino group optionally substituted with a C.sub.1 -C.sub.4 alkyl or phenyl-(C.sub.1 -C.sub.4) alkyl group,R.sub.2 is hydrogen or a hydroxy group,R.sub.3 is hydrogen or chlorine,R.sub.4 is hydrogen or a hydroxy or amino group,R.sub.5 is hydrogen or a hydroxy group, andR.sub.6 is hydrogen or a hydroxy group,or a non-toxic acid addition salt thereof, is useful in the parenteral treatment of visceral leishmaniasis or malaria, and a synergistic composition comprising a compound of formula (I) or a non-toxic acid addition salt thereof and sodium stibogluconate is useful in the treatment of visceral leishmaniasis.

Abstract: The invention relates to a pharmaceutical composition in solid unit dosage form adapted for oral administration, comprising a salt formed between ranitidine and a complex of bismuth with a carboxylic acid selected from tartaric acid and citric acid together with an alkaline salt. For example the composition is in tablet form and comprises ranitidine bismuth citrate and sodium carbonate.The composition shows improved disintegration and/or dissolution.

Abstract: A wood preservative composition including a mixture of two or more metallic soaps of long chain unsaturated fatty acids, which soaps have a metallic component selected from the group consisting of copper, zinc, chromium, iron, antimony, tin, cobalt, nickel, arsenic, boron, lead, magnesium, potassium and sodium, and a fatty acid component selected from two or more of the group consisting of oleic acid, linoleic acid, and linolenic acid, the composition being such that the ratio by mass of metallic soap of oleic acid:metallic soap of linoleic acid:metallic soap of linolenic acid is about 20-29:15-70:0-47.

Abstract: A method for treating trypanosomiases, leishmanioses, filariases and pneumonias caused by Pneumocystis carinii, comprising the step of administering an effective amount of an organometallic compound of the formula: ##STR1## in which: M is arsenic or antimony,Y and Z are identical or different and are each sulfur or oxygen,R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are identical or different and are each hydrogen or a group of the formula: ##STR2## in which X is nitrogen, andA.sub.1 is an alkylene group of 3 to 21 carbon atoms, that is unsubstituted or substituted by: one or more groups which are identical or different and which are of the formula: --(CH.sub.2).sub.n --R.sub.7 in which R.sub.7 is --H, --OH, --COOH, --NH.sub.2 or --SO.sub.3 H and n is an integer of 0 to 10; or one or more Na or K salts of said one or more groups of the formula: --(CH.sub.2).sub.n --R.sub.7, when R.sub.7 is --COOH; or one or more hydrochlorides of said one or more groups of the formula: --(CH.sub.2).sub.n --R.sub.7 when R.

Abstract: Methods, for the treatment of humans and lower animal subjects having a gastrointestinal disorder, comprising administering bismuth and administering an antimicrobial. From about 50 to about 5000 milligrams of bismuth are administered, per day, for from 3 to 56 days. A safe and effective amount of antimicrobial is administered for from 1 to 21 days. Preferred processes also include a step for performing a diagnostic test on the subject for detection of a campylobacter-like organism infection of the subject. The invention also provides compositions containing a safe and effective amount of bismuth and a safe and effective amount of antimicrobial.

Abstract: Oral pharmaceutical compositions in unit dosage form suitable for swallowing (especially capsules) comprising a safe and effective amount of solid Colloidal Bismuth Subcitrate (CBS), and optionally one or more pharmaceutically-acceptable carrier materials, wherein the packing density of the dosage unit is less than about 1 g/ml.

Abstract: The invention relates to a liquid, bismuth containing medicinal product for the oral treatment of gastro-intestinal illnesses such as gastritis, ulcers, etc., caused by campylobacter.The invention provides a closed system, e.g. a single dose container or a multiple dose container with dosing device containing one or more portions of the bismuth containing medicinal product. In addition, a simple, inexpensive production process is proposed, in which the bismuth citrate is suspended in water, slightly heated and, accompanied by the addition of caustic potash solution/aqueous ammonia solution, is dissolved and set to a pH-value between 6.0 and 7.0 Subsequently an aqueous tripotassium citrate-citric acid solution is added and if necessary sterilized. The solution obtained is placed in a multidose container with dosing device, or is initially diluted with water to form a ready to drink solution, portioned into single dose containers and optionally sterilized.

Abstract: Microbially-stable liquid pharmaceutical suspensions for oral administration comprising a bismuth-containing pharmaceutical agent, benzoic acid, sorbic acid, a suspension system and water, and wherein said compositions have a pH within the range of from about 3.0 to about 5.5. These compositions are efficacious, and have good aesthetics and good storage stability.

Abstract: Prolonged parenteral release of a bioactive polypeptide at desirably effective levels can be achieved using novel compositions in which the polypeptide is present in a biocompatible oil in an unusually high proportion such as at least about 10% by weight. Also disclosed are certain metal-associated somatotropins that are useful for prolonged parenteral release of such somatotropins.

Abstract: Disclosed are steroidal derivatives of glycolipids, in which steroids are bridged, via a medium length hydrocarbon chain, to 1-thio-D-mannopyranoses or 1-thio-L-fucopyranoses in combination with an anti-AIDS drug, that protect an immunocomprimised hot, particularly resulting from an AIDS-related virus, against opportunistic infection.

Abstract: A process for producing an effective anti-ulcer preparation in the form of a dry powder by spray-drying a colloidal solution comprising bismuth citrate, ammonia and a polyhydric alcohol.

Abstract: Pharmaceutical compositions suitable for oral administration comprising: (a) pharmaceutically-acceptable bismuth-containing agents such as bismuth subsalicylate; (b) pharmaceutically-acceptable non-ionic cellulose ether polymers such as methylcellulose; and (c) magnesium aluminum silicate. The ratio of bismuth to non-ionic cellulose ether polymer is greater than about 1.5:1. Compositions in the form of liquids containing water are preferred.This invention also relates to methods for treating or preventing disturbances of the gastrointestinal tract in humans or lower animals by orally administering a composition of the present invention.

Abstract: Metallicenium salts of the general formula I[(.eta..sup.5 --C.sub.5 H.sub.-x R.sub.x)M(.eta..sup.5 --C.sub.5 H.sub.5-y R'.sub.y)].sub.a.sup.m+ [A].sub.b.sup.n- (I)in which M is Fe, Co, Ni, Ru or Os; C.sub.5 H.sub.5-x R.sub.x and C.sub.5 H.sub.5-y R'.sub.y denote cyclopendadienyl rings which, independently of one another, can be unsubstituted (x and y=0) or mono-, di-, tri-, tetra- or penta-substituted (x and y=1, 2, 3, 4 or 5), and in which R and R' independently of one another represent identical or different substituents and denote alkyl, cycloalkyl, hydroxyalkyl, aminoalkyl, halogenoalkyl, alkenyl, aryl, aralkyl, ferrocenyl, ferrocenylium, ferrocenylalkyl, acyl, halogenyl, trialkylsilyl, tricycloalkylsilyl, triarylsilyl, triaralkylsilyl or carboxyl, ester, amide or hydrazide groups, or R and R' together form an alkylene bridge with 2 to 4 bridge atoms; a, b, m and n are integers, and m has the value 1 or 2, n has the value 1, 2 or 3 and a.times.m=b.times.

Abstract: The invention relates to a method for making a composition which comprises selecting at least one fatty acid or fatty ester compound having an allylic unsaturation of the type --CH.dbd.CH--CH.sub.2 --CH.dbd.CH-- or --CH.dbd.CH--CH.dbd.CH--CH.sub.2 --, adding to said compound a salt of an element having a rhombohedral crystal structure, such as Bi, Hg, As, B, Sb or Sm, to form a mixture, heating said mixture above about 260.degree. C. for a sufficient period of time to incorporate at least about 0.1% by weight of the element into the compound, cooling the mixture, and recovering the incorporated compound as the remaining fluid of the mixture. The invention also relates to the reaction products thus produced along with methods of administering these compositions to a subject to treat abnormal conditions caused mainly by a catabolic imbalance.

Abstract: Processes for making colored pharmaceutical compositions, by the steps of:(a) preparing an aqueous mixture having a pH of at least about 5, containing a suspension agent, and a pharmaceutically-acceptable bismuth salt at a level of from about 0.5% to about 3%, by weight of final composition;(b) adding a quantity of FD&C Red 3 dye to the mixture;(c) mixing the mixture for at least about 30 seconds; and(d) adjusting the pH of the mixture to a pH in the range of from about 3.4 to about 4.Preferably, the bismuth salt is bismuth subsalicylate. Preferred suspension agents include mixtures of magnesium aluminum silicate and methyl cellulose and of magnesium aluminum silicate and xanthan gum.

Abstract: A mixture of an extract from a plant belonging to the Zygophyllaceae family containing phenolic compositions and a nonalkali metal salt is useful as a pharmaceutical agent, for example, in the treatment of cancer, nonmalignant tumors, osteomyelitis, psoriasis and warts.

Abstract: A method of treating inflammation or arthritis with metal complexes that can traverse skin and animal cell membranes intact and effectively deliver and release metal ions in a controlled manner upon demand at the targeted inflammatory or arthritic areas containing endogenous reacting moieties which demand the metal ions. The metal complexes have an aqueous proton induced dissociation property represented by a sigmoidally-shaped curve on a cartesian coordinate plot of the negative log of the metal ion concentration versus the negative log of hydrogen ion concentration. This dissociation property enables the metal complexes to release metal ions in a controlled manner upon demand at the targeted inflammatory or arthritic areas containing endogenous reacting moieties which demand the metal ions. The metal complexes can be effectively administered either topically or subcutaneously.

Abstract: Novel methods and dental compositions for treating dental structures, such as teeth and subgingival structures, are disclosed. Uniquely, the dental compositions contain metal complexes which are characterized as having an unique aqueous proton induced dissociation property represented by a sigmoidally-shaped curve on a cartesian coordinate plot of the negative log of the metal ion concentration versus the negative log of the hydrogen ion concentration. This unique dissociation property enables the metal complexes to release therapeutic metal ions in the oral cavity for forming metal coordination complexes or salts within the dental structures. The formation of such complexes or salts within the dental structures is particularly effective and highly resistant to enzymatic degradation associated with microbial activity. Also, the metal ions of this invention are highly effective in inactivating the enzymes secreted by microbes in the oral cavity to further attenuate the disintegration process.

Abstract: Water dispersible compositions containing hydrocarbon wax are described which are useful in preparing aqueous water repellent systems. Aqueous water repellent systems containing a hydrocarbon wax also are described. The water repellent system comprises an aqueous system comprising water, a saturated hydrocarbon wax, at least one oil-soluble metal salt of an organic carboxylic acid, at least one surfactant and at least one hydrocarbon solvent. A process for impregnating permeable substrates such as wood, cloth, concrete, rope, etc. with the water repellent system is also described. Penetration of the various components into the substrate is obtained by brushing, dipping, soaking, spraying or immersion at atmospheric pressure, at elevated pressures or under vacuum. The oil-soluble metal salt often is a fungicide. Moreover, additional components can be contained in the aqueous system such as insecticides, colorants, flame retardants, moldicides, wood stabilizing agents, etc.